Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

Projecting Survival for Patients Treated With First-Line Ipilimumab-Nivolumab Combination Therapy Using a Prognostic Model and Cost Per Responder Model of Ipilimumab-Nivolumab Combination Therapy

This study will review published trial literature and documents for Overall Survival (OS) to evaluate the association between the hazard of death and each baseline variable.

Inclusion Criteria:

• Diagnosis of melanoma

Exclusion Criteria:

• Age less than 18 years old